New hope for bone sarcoma: regorafenib maintenance trial launches
NCT ID NCT04698785
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug regorafenib can help keep high-grade bone sarcomas from growing in patients who still have some disease after standard treatment. About 36 people aged 12 and older will take regorafenib daily for up to 12 months. The main goal is to see how many patients have stable disease or better after 4 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regorafenib
What this could lead to
If successful, this could point toward a new maintenance option to delay disease progression in high-grade bone sarcoma patients.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply broadly. Regorafenib can cause side effects like fatigue, diarrhea, and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHRU Hôpital Hautepierre
RECRUITINGStrasbourg, 67098, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Georges Francois Leclerc
NOT_YET_RECRUITINGDijon, 21079, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Oscar Lambret
NOT_YET_RECRUITINGLille, 59020, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Besancon
NOT_YET_RECRUITINGBesançon, 25030, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Saint-Etienne
NOT_YET_RECRUITINGSaint-Priest-en-Jarez, 42270, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital de La Timone
RECRUITINGMarseille, 13385, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hotel Dieu Nantes
NOT_YET_RECRUITINGNantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital COCHIN
RECRUITINGParis, 75014, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
ICANS
NOT_YET_RECRUITINGStrasbourg, 67200, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icm Val D'Aurelle
NOT_YET_RECRUITINGMontpellier, 34298, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ico Rene Gauducheau
RECRUITINGSaint-Herblain, 44805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Bergonie
RECRUITINGBordeaux, 33076, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Curie
RECRUITINGParis, 75005, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Iuct Oncopole
RECRUITINGToulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••